Molecular cancer therapeutics
In vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy using High-Avidity, Low-Affinity Antibodies.
Anna Kopp, Shujun Dong, Hyeyoung Kwon, Tiexin Wang, Alec A Desai, Andrew Philippart, Dong Jun Koo, Jennifer J Linderman, Peter M Tessier, Greg M Thurber
Published: 202510.1158/1535-7163.MCT-25-0576
Abstract
Antibody-drug conjugates (ADCs) have experienced a surge in clinical approvals in the past few years. Despite this success, a major limitation to ADC efficacy in solid tumors is poor tumor penetration, which leaves many cancer cells untargeted. Co-ad…
Preview only. Read the full abstract at the source